menu
    • menu
    [{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Apomivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed"},{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Arthrospira maxima","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Undisclosed","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ Undisclosed"},{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"National Taiwan University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"FB-1603","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ National Taiwan University Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ National Taiwan University Hospital"},{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"Febico (Far East Bio-Tec Co Ltd)","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Spirulina","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ Febico (Far East Bio-Tec Co Ltd)","highestDevelopmentStatusID":"1","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ Febico (Far East Bio-Tec Co Ltd)"},{"orgOrder":0,"company":"Febico (Far East Bio-Tec Co Ltd)","sponsor":"Shih Chien Huang","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"TAIWAN","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"Multicomponent Dietary Supplement","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Febico (Far East Bio-Tec Co Ltd)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Febico (Far East Bio-Tec Co Ltd) \/ Shih Chien Huang","highestDevelopmentStatusID":"1","companyTruncated":"Febico (Far East Bio-Tec Co Ltd) \/ Shih Chien Huang"}]

    Find Clinical Drug Pipeline Developments & Deals by Febico (Far East Bio-Tec Co Ltd)

    Menu

    Febico (Far East Bio-Tec Co Ltd)

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arthrospira maxima

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Inner Ear Support' Oral Capsule in Patients with Sudden Sensorineural Hearing Loss

                            Details : Arthrospira maxima is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hearing Loss, Sensorineural.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 30, 2025

                            Lead Product(s) : Arthrospira maxima

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Multicomponent Dietary Supplement

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : Shih Chien Huang

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dietary Supplementation on Tear Secretion and Inflammation in DES

                            Details : Multicomponent Dietary Supplement is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Dry Eye Syndromes.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 17, 2024

                            Lead Product(s) : Multicomponent Dietary Supplement

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : Shih Chien Huang

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FB-1603

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoem...

                            Details : FB-1603 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 27, 2024

                            Lead Product(s) : FB-1603

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : National Taiwan University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Spirulina

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : Taipei Medical University WanFang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Spirulina (FEM-102) Supplement to Chronic Hepatitis B Patients

                            Details : Spirulina is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hepatitis B, Chronic.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 22, 2021

                            Lead Product(s) : Spirulina

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : Taipei Medical University WanFang Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Febico (Far East Bio-Tec Co Ltd)

                            Taiwan arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apomivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Investigate the Efficacy and Safety of Apomivir®

                            Details : Apomivir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Influenza, Human.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 03, 2012

                            Lead Product(s) : Apomivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth